HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

Falo, Catalina; Moreno, Abelardo; Varela, Mar; Lloveras, Belén; Figueras, Agnés; Escobedo, A.

doi:10.1007/s00432-006-0176-7

Cited by 20 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in a recent study where patients with basal cancers defined by Ck14-positivity were treated with a similar regimen, a better prognosis than patients with Ck14-negative, grade matched cancers was observed [28]. In a recent retrospective analysis of a series of operable breast cancers treated with primary CMF chemotherapy by Falo and colleagues [45], TN tumours were found to have the highest response rates (64.9%). Patients in the study who had the combination of response to CMF and HER2 negative tumours also emerged with the best outcome [45].…”

Section: Discussionmentioning

confidence: 94%

“…In a recent retrospective analysis of a series of operable breast cancers treated with primary CMF chemotherapy by Falo and colleagues [45], TN tumours were found to have the highest response rates (64.9%). Patients in the study who had the combination of response to CMF and HER2 negative tumours also emerged with the best outcome [45]. Furthermore, in a large randomised study of sequential anthracycline and paclitaxel followed by CMF comprising 1355 patients [46], complete pathological response was observed in 42% of ER negative tumours in the neoadjuvant treatment arm, and ER negative status was the only significant variable independently associated with both clinical and pathological complete response across the whole cohort.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

Tan

Marchiò

Jones

et al. 2007

Breast Cancer Res Treat

280

212

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 97%

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

Tan

Marchiò

Jones

et al. 2007

Breast Cancer Res Treat

280

212

View full text Add to dashboard Cite

show abstract

“…Multi-drug resistance to chemotherapeutic agents is a major cause of treatment failure in breast cancer, because chemotherapy plays ever increasing role in the systemic treatment modalities of breast cancer both in neoadjuvant and adjuvant chemotherapy [19,20]. For patients who cannot obtain clinical remission during adjuvant chemotherapy and those with recurrence and metastasis after initial treatment, reversal of multi-drug resistance is of crucial importance for improving clinical outcome [21,22].…”

Section: Discussionmentioning

confidence: 99%

Emodin affects ERCC1 expression in breast cancer cells

Zhou

Shi

et al. 2012

J Transl Med

View full text Add to dashboard Cite

BackgroundMulti-drug resistance to chemotherapeutic agents is a major cause of treatment failure in breast cancer. In this study, we investigated the effects of emodin on reversing the multi-drug resistance, examined the ERCC1 protein expression in breast cancer cell line, and explored the relationship between reversal of multi-drug resistance and ERCC1 protein expression.MethodsMTT assay was conducted to test the cytotoxicity of adriamycin and cisplatin to MCF-7/Adr cells with and without emodin pretreatment, and Western blot was performed to examine the ERCC1 protein expression.ResultsMCF-7/Adr cells had 21-fold and 11-fold baseline resistances to adriamycin and cisplatin, respectively. When emodin was added to the cell culture at the concentration of 10 μg/ml, the drug resistance was reduced from 21 folds to 2.86 folds for adriamycin, and from 11 folds to 1.79 folds for cisplatin. MCF-7/Adr cells treated with two concentrations (10μg/mL and 20μg/mL) of emodin, after 2, 4, 6, 10 days, the trend of ERCC1 expression was gradually decreased and the reduction was more obvious comparatively at the concentration of 20μg/mL.ConclusionsEmodin could reverse the multi-drug resistance in MCF-7/Adr cells and down-regulate ERCC1 protein expression.

show abstract

“…The luminal types respond well to hormone therapy and have a good prognosis, while the Her2overexpression type has a worse prognosis than the luminal types but responds well to trastuzumab therapy [2][3][4]. On the other hand, the BP type accounts for approximately 15% of all breast cancers, exhibits a high degree of malignancy and is said to have a poor prognosis due to an inadequate response to chemotherapy [8,14].…”

Section: Discussionmentioning

confidence: 99%

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple‐negative breast cancer

Sasa

Bando

Takahashi

et al. 2007

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: Triple-negative breast cancer (estrogen receptor-negative, progesterone receptor-negative and Her2-negative) can be classified into two subtypes: basal and non-basal phenotype. Among these subtypes the basal phenotype is associated with poor outcome. Ordinarily, clinicopathological testing involves only screening for ER, PgR and Her2, and for this reason the therapeutic approach that is decided for triplenegative disease is usually the same regardless of the subtype. Methods: Immunohistochemical staining was performed for the CK5/6, CK14, and CK17 basal markers in 66 triple-negative patients for the purpose of classifying as basal or non-basal phenotype, and the clinicopathology was investigated. Results: Forty (60.1%) were the basal phenotype. Compared with the non-basal phenotype, the basal phenotype lesions were significantly larger in diameter, higher incidences of EGFR-positive and a high nuclear grade. In the node-negative group the basal phenotype clearly showed those same clinicopathological differences and a higher incidence of distal recurrence compared with the non-basal phenotype. Conclusions: Although there was the small number of the patients, this study results show that it is important to perform basal marker immunohistochemical staining and classify lesions as the basal or the non-basal phenotype, since this will aid in deciding the therapeutic strategy for triple-negative breast cancer.

show abstract

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

Abstract: CMF indication is independent of Her-2/neu status.

Cited by 20 publications

References 26 publications

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

Emodin affects ERCC1 expression in breast cancer cells

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple‐negative breast cancer

Contact Info

Product

Resources

About